• Cells for HSCT may be obtained from the patient himself or herself (autologous transplant) or from another person, such as a sibling or unrelated donor (allogeneic transplant) or an identical twin (syngeneic transplant). (medscape.com)
  • Hepatosplenic T-cell lymphoma is a rare form of lymphoma that is generally incurable, except in the case of an allogeneic stem cell transplant. (wikipedia.org)
  • Purpose Conventional allogeneic hematopoietic stem cell transplantation (HSCT) for multiple myeloma is certainly connected with a higher transplant-related mortality (TRM). (informationalwebs.com)
  • solid course="kwd-title" Keywords: multiple myeloma, stem cell transplant, autologous, allogeneic Launch Conventional allogeneic hematopoietic stem cell transplantation (HSCT) in multiple myeloma (MM) sufferers is certainly connected with a transplant-related mortality (TRM) which range from 20C60%1C3. (informationalwebs.com)
  • Subsequently, initiatives to further decrease the transplant-related morbidity and mortality possess resulted in much less poisonous non-myeloablative allogeneic transplant (NST) regimens to. (informationalwebs.com)
  • Furthermore, previously studies confirmed that donor lymphocyte infusions (DLI) affected a graft-versus-myeloma Crizotinib inhibitor database (GVM) impact in patients with prolonged/relapsed disease following allogeneic transplant. (informationalwebs.com)
  • This lead to the development of ECOG E1A97, utilizing DLI for relapsed/prolonged myeloma post-allogeneic transplant. (informationalwebs.com)
  • There was no restriction of prior lines of therapy except prior autologous or allogeneic transplant. (informationalwebs.com)
  • The standard management of these patients includes high-dose chemotherapy followed by autologous stem cell transplant. (hindawi.com)
  • A significant number of patients who relapse after stem cell transplant do so in previously involved sites and may present with disease that could be encompassed in a radiation field. (hindawi.com)
  • Transplant Cell Ther. (stembook.org)
  • Peripheral blood stem cell (PBSC) transplant uses stem cells from the patient or a donor and may be able to replace immune cells that were destroyed by chemotherapy. (mycancergenome.org)
  • Bone marrow transplant known as a nonmyeloablative transplant uses stem cells from a haploidentical family donor. (mycancergenome.org)
  • Post-transplant lymphoproliferative disorder (PTLD) is a common and serious complication of solid organ transplantation. (cancernetwork.com)
  • they include younger age and pre-transplant EBV naivety, as well as the degree and type of immune suppression, type of organ transplantation, and time from transplantation. (cancernetwork.com)
  • Post-transplant lymphoproliferative disorders (PTLDs) are a relatively common and significant complication following solid organ transplantation, occurring in up to 10% of adult patients. (cancernetwork.com)
  • 2.2.1 Autologous Bone Marrow Transplant (ABMT), where the patient is both donor and recipient of stem cells harvested from the bone marrow. (health.mil)
  • High dose chemotherapy followed by hematopoietic stem cell transplant wasrecommended for young fit patients who achieve a response after salvage chemoimmunotherapy. (health-articles.net)
  • Blood and Marrow Transplant Research [CIBMTR] in 2004), the European Research Project on Cord Blood Transplantation (Eurocord) in 1993, and the Japanese Cord Blood Banking Network in 1996-expedited the clinical evaluation of the efficacy and safety of transplantation of cord blood from unrelated donors. (nationalacademies.org)
  • Aetna considers non-myeloablative allogeneic hematopoietic cell transplantation medically necessary ("mini-transplant", reduced intensity conditioning transplant) for the treatment of persons with relapsed NHL (including persons who have relapsed after ABMT) or primary refractory (see note below) NHL (low-grade, intermediate-grade, and high-grade) when they are eligible for conventional allografting or a reduced intensity regimen is preferred by the transplant center. (aetna.com)
  • This was a Phase 1, open-label, multicenter, study of checkpoint inhibitor therapy (tremelimumab ± durvalumab) prior to and following autologous stem cell transplant (ASCT) and high-dose melphalan in subjects with multiple myeloma who were at a high risk for relapse, were eligible for ASCT, and had available cryopreserved stem cells. (clincosm.com)
  • The study will test if patients receiving transplant using either a low dose busulfan or a medium dose busulfan will have immune recovery of both T and B cells, measured by the ability to respond to immunizations after transplant. (researcherprofiles.org)
  • Donors used for transplant must be unrelated or half-matched related (haploidentical) donors, and peripheral blood stem cells must be used. (researcherprofiles.org)
  • Once the stem cell transplant is completed, patients will be followed for 3 years. (researcherprofiles.org)
  • Related donor Adenovirus (ADV) specific cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered intravenously in in children, adolescents and young adults with refractory ADV infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant. (researcherprofiles.org)
  • Related donor Epstein-Barr Virus (EBV) specific cytotoxic T cells (CTLs) manufactured with the Miltenyi CliniMACS Prodigy Cytokine Capture System will be administered in children, adolescents and young adults with refractory EBV infection post Allogeneic Hematopoietic Stem Cell Transplantation (AlloHSCT), with primary immunodeficiencies (PID) or post solid organ transplant. (researcherprofiles.org)
  • when one definite or one possible case of laboratory-confirmed health-care--associated Legionnaires disease is identified in an inpatient hemopoietic stem-cell transplant (HSCT) recipient or in two or more HSCT recipients who had visited an outpatient HSCT unit during all or part of the 2--10 day period before illness onset. (cdc.gov)
  • [ 1 ] More than half of autologous transplantations are performed for multiple myeloma and non-Hodgkin lymphoma , and the vast majority of allogeneic transplants are performed for hematologic and lymphoid cancers. (medscape.com)
  • Multiple myeloma is a cancer of plasma cells that produce monoclonal immunoglobulin and invade and destroy adjacent bone tissue. (msdmanuals.com)
  • After enrollment of 6 subjects in Cohort 1, the study was placed on partial clinical hold by the Food and Drug Administration (FDA) due to safety signals observed in other studies investigating pembrolizumab, an anti-programmed cell death-1 (PD-1) antibody, in combination with immunomodulatory agents in subjects with multiple myeloma. (clincosm.com)
  • The invention also provides host cells, such as T-cells or natural killer (NK) cells, expressing the CAR and methods for destroying multiple myeloma cells. (justia.com)
  • Multiple myeloma (MM) is a malignancy characterized by an accumulation of clonal plasma cells (see, e.g. (justia.com)
  • This phase 2, nonrandomized, single-arm, open-label study evaluated the efficacy and safety of intravenous darinaparsin (300 mg/m 2 over 1 hour, once daily for 5 consecutive days, per 21-day cycle) and its pharmacokinetics at multiple doses in 65 Asian patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). (ashpublications.org)
  • About half of all patients undergoing ASCT are rescued and definitely cured by such an approach, but the outcome of patients relapsing or refractory to second-line chemotherapy and ASCT is dismal, with a median survival of less than three years [ 4 ]. (hindawi.com)
  • One of the most important and widely accepted prognostic factors for patients undergoing ASCT appears to be chemosensitivity at relapse, with patients responding to second-line chemotherapy and having a much better outcome than patients with refractory disease, whose relapse rate approaches 80% in some published series [ 5 , 6 ]. (hindawi.com)
  • Double epigenetic modulation of high-dose chemotherapy with azacitidine and vorinostat for patients with refractory or poor-risk relapsed lymphoma. (stembook.org)
  • Vorinostat Combined with High-Dose Gemcitabine, Busulfan and Melphalan with Autologous Stem-Cell Transplantation in Patients with Refractory Lymphomas. (stembook.org)
  • Chimeric antigen receptor T (CAR-T) cells are a promising new treatment for patients with relapsed or refractory hematologic malignancies, including lymphoma. (biomedcentral.com)
  • Recently, two clinical trials of CD30-directed CAR-T cells in relapsed/refractory CD30+ lymphomas, including Hodgkin lymphoma, have been reported with minimal toxicities noted and preliminary efficacy seen in a proportion of patients. (biomedcentral.com)
  • Several ongoing and upcoming clinical trials of CD30-directed CAR-T cells are expected to further enhance this approach to treat patients with relapsed and refractory CD30+ lymphomas. (biomedcentral.com)
  • Aetna considers autologous hematopoietic cell transplantation for the treatment of persons with relapsed or primary refractory (see "Note" below) non-Hodgkin's lymphoma (NHL) medically necessary if the person meets the transplanting institution's protocol eligibility criteria. (aetna.com)
  • Aetna considers allogeneic hematopoietic cell transplantation medically necessary for the treatment of persons with relapsed NHL (including persons who have relapsed after autologous hematopoietic cell transplantation) or primary refractory (see "Note" below) NHL (low-grade, intermediate-grade, and high-grade) if the person meets the transplanting institution's protocol eligibility criteria. (aetna.com)
  • In one of their reports, 2 out of 3 refractory CLL patients receiving CD19 CAR T cells therapy achieved complete response (CR), and another patient demonstrated partial response (PR) [ 4 ]. (biomedcentral.com)
  • In the current WHO classification, they are categorized as extranodal NK/T-cell lymphoma, nasal type and aggressive NK-cell leukemia. (medscape.com)
  • The lymphoma cells are CD2 + , cytoplasmic CD3ɛ + and CD56 + , with germline T-cell receptor gene. (medscape.com)
  • Clinically, NK-cell lymphomas can be classified into nasal, non-nasal and aggressive lymphoma/leukemia subtypes. (medscape.com)
  • Chemotherapy is indicated for stage III/IV nasal NK-cell lymphoma, and the non-nasal and aggressive subtypes. (medscape.com)
  • Mantle cell lymphoma (MCL) is a non-Hodgkin lymphoma characterized by involvement of the lymph nodes, spleen, blood and bone marrow with a short remission duration to standard therapies and a median overall survival (OS) of 4-5 years. (nih.gov)
  • The typical clinical finding in a patient with hepatosplenic T-cell lymphoma is hepatosplenomegaly. (wikipedia.org)
  • citation needed] Cases of hepatosplenic T-cell lymphoma have been reported in patients treated with the immunosuppressants azathioprine, infliximab, and adalimumab. (wikipedia.org)
  • The neoplastic cells in hepatosplenic T-cell lymphoma show a monotonous appearance, with a small amount of cytoplasm and inconspicuous nucleoli. (wikipedia.org)
  • The constellation of thrombocytopenia, anemia, and leukopenia is common in patients with hepatosplenic T-cell lymphoma. (wikipedia.org)
  • The immunophenotype for hepatosplenic T-cell lymphoma is a post-thymic, immature T-cell. (wikipedia.org)
  • Clonal rearrangement of the γ gene of the T-cell receptor is the hallmark of hepatosplenic T-cell lymphoma. (wikipedia.org)
  • citation needed] Allogeneic bone marrow transplantation has been shown to induce remission for more than five years and possibly cure hepatosplenic lymphoma. (wikipedia.org)
  • FDA Warning concerning azathioprine and Hepatosplenic T-cell lymphoma https://www.fda.gov/Safety/MedWatch/SafetyInformation/ucm258794.htm Ross CW, Schnitzer B, Sheldon S, Braun DK, Hanson CA (September 1994). (wikipedia.org)
  • 22. Expression of the adhesion molecules CD49d and CD49e on G-CSF-mobilized CD34+ cells of patients with solid tumors or non-Hodgkin's and Hodgkin's lymphoma and of healthy donors is inversely correlated with the amount of mobilized CD34+ cells. (nih.gov)
  • 31. Elimination of bcl-2-IgH-positive follicular lymphoma cells from blood transplants with high recovery of hematopoietic progenitors by the miltenyi CD34+ cell sorting system. (nih.gov)
  • Despite a high clinical success, relapse in Hodgkin lymphoma occurs in 10-30% of cases and 5-10% patients are nonresponsive to initial chemotherapy. (hindawi.com)
  • Cutaneous T-cell lymphoma (CTCL) (see the image below) is a heterogeneous group of lymphoproliferative disorders characterized by localization of neoplastic T lymphocytes to the skin, with no evidence of extracutaneous disease at the time of diagnosis. (medscape.com)
  • Early patch-stage cutaneous T-cell lymphoma. (medscape.com)
  • Related articles include Cutaneous B-Cell Lymphoma and Cutaneous Pseudolymphoma . (medscape.com)
  • Among the changes to CTCL classification were the addition of primary cutaneous acral CD8 + T-cell lymphoma as a new provisional entity. (medscape.com)
  • Also, the term "primary cutaneous CD4 + small/medium T-cell lymphoma" was changed to "primary cutaneous CD4 + small/medium T-cell lymphoproliferative disorder" because of its indolent clinical behavior and uncertain malignant potential. (medscape.com)
  • 2015 Discovery of a more sensitive biomarker to predict relapse in patients with diffuse large B-cell lymphoma. (nih.gov)
  • CD30 is promising target as it is universally expressed in virtually all classical Hodgkin lymphomas, anaplastic large cell lymphomas, and in a proportion of other lymphoma types, including cutaneous T cell lymphomas and diffuse large B cell lymphomas. (biomedcentral.com)
  • However alternative targets are needed for other types of lymphoma that lack CD19 expression, including diseases like classical Hodgkin lymphoma (HL), anaplastic large cell lymphoma (ALCL) and other T-cell lymphomas. (biomedcentral.com)
  • ALCL is a subtype of peripheral T cell lymphoma with heterogeneous characteristics [ 9 ]. (biomedcentral.com)
  • Although Hodgkin's lymphoma (HL) was one of the first human cancers to be cured by chemotherapy, no new agents other than brentuximab vedotin ( Adcetris®, CD 30 directed antibody drug conjugate) have received US Food and Drug Administration (FDA) approval for HL since 1977. (oncotarget.com)
  • 2012 Wiley Periodicals, Inc. consecutive consensus conferences, the issues were analyzed and dis- Follicular cell lymphoma (FL) is a frequent disorder for cussed according to the nominal group technique, as previously described [5]. (health-articles.net)
  • In the 2008 WHO classification, grade 3b FL were separated and are universally treated as diffuse large reported the clinical outcomes in patients in which the ther- B-cell lymphoma (DLBCL) [2]. (health-articles.net)
  • This Clinical Policy Bulletin addresses hematopoietic cell transplantation for non-hodgkin's lymphoma. (aetna.com)
  • The purpose of this study is to characterize the molecular and cell biology of the tumor cells in lymphoma. (stanford.edu)
  • This phase 1-2 trial studies the side effects and best dose of ipilimumab in combination with toll-like receptor 9 (TLR9) agonist SD-101 and radiation therapy in treating patients with recurrent low-grade B-cell lymphoma. (stanford.edu)
  • Adoptively transferred anti-CD19-CAR-transduced T-cells have cured leukemia and lymphoma in mice (see, e.g. (justia.com)
  • In early clinical trials, adoptively transferred T-cells transduced with anti-CD19 CARs eradicated normal and malignant B-cells in patients with leukemia and lymphoma (see, e.g. (justia.com)
  • In doing so, the overarching goal of the Collaborative Research Center is to create and strengthen synergies towards the discovery of patho-mechanisms and the identification of innovative therapeutic strategies beyond the lymphoma cell-autonomous level. (sfb1530.de)
  • Improved patient outcomes can only be achieved in an interdisciplinary approach and strengthening of synergies towards the discovery of pathomechanisms and the identification of innovative therapeutic strategies beyond the lymphoma cell-autonomous level. (sfb1530.de)
  • The SFB1530 brings together the synergistic combination of efficient disruption of lymphoma cell-intrinsic oncogenic programs and a specific modulation of the lymphoma (immune) microenvironment. (sfb1530.de)
  • Macrophages in the B-cell lymphoma microenvironment represent a functional node in progression and therapeutic response. (sfb1530.de)
  • Pentose phosphate pathway (PPP) inhibition by specific compounds and shRNA targeting induced increased phagocytic lymphoma cell clearance. (sfb1530.de)
  • Moreover, macrophages provided decreased support for survival of lymphoma cells. (sfb1530.de)
  • Addition of the PPP inhibitor S3 to antibody therapy achieved significantly prolonged overall survival in an aggressive B-cell lymphoma mouse model. (sfb1530.de)
  • To date, the most encouraging clinical observations have been achieved from patients with chronic lymphocytic leukemia (CLL) and lymphoma treated by CD19-orientated CAR T cells [ 3 ]. (biomedcentral.com)
  • CD19 is expressed on most types of B-cell leukemia/lymphoma but absent in non-B lineage cells. (biomedcentral.com)
  • When treated solely with chemotherapy, most patients relapse and die within two years. (wikipedia.org)
  • Leukemic cells failed to clear in one patient with end-stage disease, and a relapse with meningeal leukemia occurred in another. (nih.gov)
  • Subsets of young adult patients with HL continue to relapse, even after stem cell transplantation, warranting new approaches. (oncotarget.com)
  • PFS included all patients peripheral blood progenitor cell (PBPC) harvesting, HDS and and was calculated from HDCY date until the date of ASCT.9 progression, relapse, last follow-up or death due to any cause. (bvsalud.org)
  • Autologous stem cell transplantation (ASCT) is the standard of care for patients with relapsed HL [ 3 ]. (hindawi.com)
  • Salvage therapy for patients with chemosensitive disease generally consists of high dose chemotherapy followed by ASCT. (biomedcentral.com)
  • Leukopheresis was performed on Days -10 to -3, followed by high dose therapy (HDT) comprising melphalan (200 mg/m^2) administered intravenously (IV) on Day -2, and ASCT using previously banked hematopoietic stem cells on Day 0. (clincosm.com)
  • Autologous PBLs were re-infused into subjects on Day +3 following ASCT, with a single dose of tremelimumab (75 mg) administered on the same day. (clincosm.com)
  • and (3) ASCT, but without BV after transplantation. (ascopubs.org)
  • Hematopoietic stem cell transplantation (HSCT) involves the intravenous infusion of hematopoietic stem cells in order to reestablish blood cell production in patients whose bone marrow or immune system is damaged or defective. (medscape.com)
  • The National Marrow Donor Program (NMDP), founded in 1986, and the World Marrow Donor Association (WMDA), founded in 1988, were established to (1) locate and secure appropriate unrelated-donor HSCT sources for patients by promoting volunteer donation of bone marrow and peripheral blood stem cells in the community and (2) promote ethical practices of sharing stem cell sources by need, rather than by geographic location of the donor. (medscape.com)
  • This, along with the development of unrelated cord blood transplantation and familial haploidentical transplantation methods, have improved the likelihood of finding an appropriate HSCT source in a timely manner. (medscape.com)
  • Conclusions Autologous HSCT accompanied by NST is certainly feasible with a minimal early TRM within a cooperative Crizotinib inhibitor database group placing. (informationalwebs.com)
  • The entire response price was 78% including 30% CR-similar to various other reviews for autologous HSCT-NST. (informationalwebs.com)
  • Subsequent approaches investigated tandem transplants earlier in the disease course: high dose therapy with autologous HSCT to provide maximal tumor cytoreduction followed by NST to eradicate minimal residual disease through the GVM effect9C15. (informationalwebs.com)
  • We statement the combined results of ECOG E4A98, a Phase II trial of autologous HSCT for maximal tumor cytoreduction followed by a matched sibling NST to allow for any GVM effect. (informationalwebs.com)
  • High Dosage Melphalan/Autologous HSCT 32 patients, using a gathered Rabbit Polyclonal to OR1A1 the least 2 106 Compact disc34+ cells/kg previously, had been enrolled and received high dosage melphalan 200 mg/m2 as an individual dosage IV over 5 -15 a few minutes within thirty minutes of reconstitution on Time -1. (informationalwebs.com)
  • Adoptive transfer of in vitro-generated, Ag-specific T cells has recently emerged as a therapeutically effective approach for the prevention and/or treatment of potentially lethal infections caused by CMV and EBV complicating allogeneic hematopoietic stem cell transplants (HSCT) 3 or organ transplants ( 1 , 2 , 3 , 4 , 5 , 6 ). (aai.org)
  • In the section on aspergillosis, the revised recommendations include the use of a room with high-efficiency particulate air filters rather than laminar airflow as the protective environment for allogeneic HSCT recipients and the use of high-efficiency respiratory-protection devices (e.g. (cdc.gov)
  • The Cellular Immunotherapy of Cancer study section will focus on the many approaches to cellular therapy, including stem cell transplantation, adoptive cellular therapies and their toxicities, as well as therapeutic combinations that employ adoptive and allogeneic cell transfer. (nih.gov)
  • Adoptive cellular therapies (TILs, CAR- and TCR-engineered T cells, NK/NKT cells) using immune cells as cancer treatment. (nih.gov)
  • 2010 Study suggests that adoptive transfer of genetically engineered autologous cells can treat patients with b-cell lymphomas. (nih.gov)
  • In specific embodiments, the disclosure concerns adoptive cell therapy cancer treatment in which tumor-1 infiltrating lymphocytes and/or engineered T cells are modified to increase their efficacy as a cancer treatment. (justia.com)
  • The disclosure particularly concerns adoptive cell therapies for individuals with cancer, including methods and compositions that allow immunotherapies to work more effectively for killing cancer cells of any kind. (justia.com)
  • Particular embodiments of the disclosure concern modulation of particular immune cell surface proteins to enhance adoptive cell therapy, and in specific cases the immune cells are lymphoid cells, including at least T cells, tumor infiltrating lymphocytes, or B cells, for example. (justia.com)
  • This disclosure provides adoptive cell therapy embodiments that allow therapeutic efficacy in individuals with cancer, including solid tumors. (justia.com)
  • Adoptive transfer of virus-specific T cells can treat infections complicating allogeneic hematopoietic cell transplants. (aai.org)
  • This replenishable panel of AAPCs can be used for immediate sensitization and expansion of virus-specific T cells of desired HLA restriction for adoptive immunotherapy. (aai.org)
  • Adoptive transfer of T-cells genetically modified to recognize malignancy-associated antigens is showing promise as a new approach to treating cancer (see, e.g. (justia.com)
  • For B-cell lineage malignancies, extensive progress has been made in developing adoptive T-cell approaches that utilize anti-CD19 CARs (see, e.g. (justia.com)
  • Adoptive immunotherapy (AIT) using this supernatural T cell have gained momentum after decades of intense debates because of the promising results obtained from preclinical models and clinical trials. (biomedcentral.com)
  • Adoptive immunotherapy (AIT) using chimeric antigen receptor-engineered T cells is a promising approach in cancer treatment. (biomedcentral.com)
  • The efficacy and safety of adoptive CAR-engineered T cells have been evaluated in multiple oncological settings. (biomedcentral.com)
  • The purpose is to deliver chemotherapy, immunotherapy, and/or radiation to eliminate malignancy, prevent rejection of new stem cells, and create space for the new cells. (medscape.com)
  • Applications that focus on involving preclinical cellular immunotherapy and combination with immunotherapy/chemotherapy may be reviewed in CIC. (nih.gov)
  • 2017 A new immunotherapy for Merkel cell carcinoma, a rare type of skin cancer. (nih.gov)
  • 2011 Durable and complete response for T cell transfer immunotherapy confirmed for patients with metastatic melanoma. (nih.gov)
  • Several CCIR members are investigating the development and function of innate immune cells and receptor-mediated signal transduction pathways leading to expression of cytokines and costimulatory molecules involved in T cell activation and differentiation in order to find ways to enable cancer immunotherapy to activate innate immunity leading to durable anti-tumor T cell responses. (mdanderson.org)
  • The long-term efficacy seen with the dual immunotherapy regimen in CheckMate -227 reinforce the importance of nivolumab plus ipilimumab to transform outcomes for appropriate patients with metastatic non-small cell lung cancer. (minyanville.com)
  • We are ecstatic to see Opdivo plus Yervoy continue to demonstrate almost double the overall survival rates as chemotherapy after six years of follow-up - the longest-ever for a Phase 3 trial with immunotherapy in metastatic non-small cell lung cancer. (minyanville.com)
  • Immunotherapy with flotetuzumab may induce changes in the body's immune system and may interfere with the ability of leukemia cells to grow and spread. (ucsf.edu)
  • Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. (stanford.edu)
  • Taking into account the important function of Tregs in the control of autoimmunity and oncogenesis, approaches to immunotherapy of inflammatory pathologies based on autologous and donor Tregs, as well as methods of activating an antitumor immune response as a result of selective blockade of the functional activity of Tregs, are being actively developed. (genescells.ru)
  • Recent years have witnessed much progress in both basic research and clinical trials regarding cancer immunotherapy with chimeric antigen receptor (CAR)-engineered T cells. (biomedcentral.com)
  • 29. Factors affecting hemopoietic recovery after high-dose therapy and autologous peripheral blood progenitor cell transplantation: a single center experience. (nih.gov)
  • 30. Peripheral blood progenitor cell (PBPC) counts during steady-state haemopoiesis enable the estimation of the yield of mobilized PBPC after granulocyte colony-stimulating factor supported cytotoxic chemotherapy: an update on 100 patients. (nih.gov)
  • PTLD following hematopoietic stem cell transplantation is usually a malignancy of donor lymphoid cells, whereas PTLD following solid organ transplantation is traditionally thought to be of recipient origin in the majority of cases, though donor-derived cases have been reported and typically involve the grafted organ. (cancernetwork.com)
  • 2.2 Stem cell "transplantation" or "rescue" is defined as a technique for collecting stem cells from a donor (either from the bone marrow or from the bloodstream), preparing and storing the collected stem cells, then reinfusing the prepared stem cells into the bloodstream of a patient in the treatment of oncologic, hematologic or lymphoproliferative disease with curative potential. (health.mil)
  • 2.2.2 Autologous Peripheral Stem Cell Transplantation (PSCT), where the patient is both donor and recipient of stem cells harvested from the bloodstream using the apheresis process. (health.mil)
  • 2.2.3 Allogeneic Bone Marrow Transplantation (BMT), where stem cells from a histocompatible donor (other than the patient) are harvested from the bone marrow, then later infused into the bloodstream of the patient. (health.mil)
  • With BMT, the patient may have either a related or unrelated donor who has the same or closely matched Human Leukocyte Antigen (HLA) typing necessary for successful transplantation. (health.mil)
  • Clinical trials using donor T cells specific for alloantigen ( 5 ) or oncofetal proteins differentially expressed by host tumors are also being explored ( 7 , 8 , 9 ). (aai.org)
  • Natural killer (NK)-cell malignancies are uncommon neoplasms, which have been referred to as polymorphic reticulosis or angiocentric T-cell lymphomas in the past. (medscape.com)
  • Pathologically, NK-cell lymphomas show a polymorphic neoplastic infiltrate with angioinvasion and angiodestruction. (medscape.com)
  • Most nasal NK-cell lymphomas present with stage I/II disease. (medscape.com)
  • Most, if not all, of such cases probably represent primary cutaneous CD30 + pleomorphic, medium or large cell T-cell lymphomas. (medscape.com)
  • For purposes of coverage, mantle cell lymphomas will be considered as intermediate grade, non-Hodgkin's lymphomas. (health.mil)
  • Given the success of CAR-T cells directed against CD19, new targets are being developed and tested, since not all lymphomas express CD19. (biomedcentral.com)
  • CD19 is a rational target for B-cell malignancies, including lymphomas, as it is expressed on B cells during all stages of differentiation as well as in cells that have malignantly transformed [ 3 ]. (biomedcentral.com)
  • 2011 Genetically engineered lymphocytes reactive with NY-ESO-1, a cancer/testis antigen, may cause tumor regression in patients with metastatic synovial cell sarcoma and melanoma. (nih.gov)
  • 2003 Findings suggest the administration of cytotoxic T lymphocyte-associated antigen 4 can mediate the regression of metastatic melanoma. (nih.gov)
  • Li H, Hong S, Qian J, Zheng Y, Yang J, Yi Q. Cross talk between the bone and immune systems: osteoclasts function as antigen-presenting cells and activate CD4+ and CD8+ T cells. (mdanderson.org)
  • Chimeric antigen receptor T (CAR-T) cells have shown remarkable activity in hematologic malignancies. (biomedcentral.com)
  • CAR molecules are created by fusing the single chain variable fragment (scFv) derived from an antibody targeting a surface antigen with the T cell signaling domain [ 1 , 2 ]. (biomedcentral.com)
  • 2003). After the early success of transplantation of cord blood from related donors, cord blood banks were established to provide rapidly accessible, human leukocyte antigen (HLA)-typed units predominantly for transplantation of HPCs from unrelated donors. (nationalacademies.org)
  • Antibody- and T-cell-based approaches to targeting of B-cell maturation antigen have shown efficacy. (msdmanuals.com)
  • In specific cases, the cells are engineered for knock out of one or more genes, such as Signaling Threshold Regulating Transmembrane Adaptor 1 (SIT1), Bone Marrow Stromal Cell Antigen 2 (BST2), and/or programmed cell death protein 1 (PD-1). (justia.com)
  • In particular embodiments, the genes that are knocked out or knocked down are Signaling Threshold Regulating Transmembrane Adaptor 1 (SIT1), Bone Marrow Stromal Cell Antigen 2 (BST2), and Programmed cell death protein 1 (PD-1). (justia.com)
  • The invention provides an isolated and purified nucleic acid sequence encoding a chimeric antigen receptor (CAR) directed against B-cell Maturation Antigen (BCMA). (justia.com)
  • T-cells can be genetically modified to express chimeric antigen receptors (CARs), which are fusion proteins comprised of an antigen recognition moiety and T-cell activation domains (see, e.g. (justia.com)
  • Read S., Malmstrom V., Powrie F. Cytotoxic T lymphocyte-associated antigen 4 plays an essential role in the function of CD25(+)CD4(+) regulatory cells that control intestinal inflammation. (genescells.ru)
  • Incorporation of a single chain variable fragment (scFv) of a tumor antigen specific antibody and signaling domains of T cell receptor (TCR) renders chimeric antigen receptor (CAR) the specificity of antibody as well as the cytotoxicity of cytotoxic T lymphocytes (CTLs) [ 1 ]. (biomedcentral.com)
  • CAR endows T cells antigen specific recognition, activation and proliferation in an MHC independent manner. (biomedcentral.com)
  • Worldwide, approximately 90,000 first HSCTs-53% autologous and 47% allogeneic-are performed every year, according to the World Wide Network of Blood and Marrow Transplantation. (medscape.com)
  • CONCLUSIONS Our study showed that biosimilar G-CSF (Zarzio®) has comparable efficacy to the original G-CSF (Neupogen®) when used for mobilization in both autologous and allogenic stem cell transplantation and was associated with significant cost saving. (bvsalud.org)
  • However, improving the persistence and expansion of CAR-T cells is key to further enhancing the efficacy of this treatment approach. (biomedcentral.com)
  • The aim of this study is to assess the safety and efficacy of autologous transplantation of hematopoietic stem cells (CD34+ cells) from mobilized peripheral blood (mPB) of ADA-deficient SCID infants and children following human ADA gene transfer by the EFS-ADA lentiviral vector. (researcherprofiles.org)
  • The methods and compositions increase efficacy of the cells for the therapy in at least some cases by allowing them to overcome immunosuppression at the tumor microenvironment. (justia.com)
  • The modulation of expression of the genes in the cells may be for the explicit purpose of improving efficacy of the cells for therapy, including improving efficacy in the tumor microenvironment. (justia.com)
  • In this review, we will briefly discuss the critical issues related to the antitumor efficacy including the structure of CAR, the potential of T cells subsets, the gene modification of lymphocytes, the preconditioning regimens, etc. (biomedcentral.com)
  • The CHOP chemotherapy regimen frequently induces remission but has proven weak compared to treatments that integrate cytarabine, with Hyper-CVAD being particularly effective. (wikipedia.org)
  • Survival was favorably affected by younger age and transplantation during first remission. (nih.gov)
  • We conclude that high-dose chemotherapy with busulfan and cyclophosphamide, followed by allogeneic-marrow transplantation, can produce long-term remission of acute leukemia. (nih.gov)
  • 2001 Immunotoxin BL22 can potentially induce complete remission in patients with Hairy-cell leukemia. (nih.gov)
  • This proof of concept clinical investigations have demonstrated an excellent cell engraftment (up to 3 log expansion) and tumor cell lysis, eventually leading to complete remission. (biomedcentral.com)
  • Natural killer (NK) cells are cytotoxic cells capable of targeting tumor cells and bacteria- and virus-infected cells. (medscape.com)
  • In vivo delivery of TK-NTR and administration of prodrugs led to the effective killing of both targeted cells and surrounding tumor cells via TK-NTR-mediated conversion of co-delivered prodrugs into active cytotoxic agents. (regenerativemedicine.net)
  • In vivo evaluation of the bystander effect in mouse models demonstrated that for effective therapy, at least 1% of tumor cells need to be delivered with TK-NTR-encoding MCs. (regenerativemedicine.net)
  • [ 1 ] Morphologically, NK cells appear as large granular lymphocytes, showing an abundant pale cytoplasm with azurophilic granules. (medscape.com)
  • Although NK cells represent a distinct lineage of lymphocytes that are different from T cells, the two lineages are developmentally related. (medscape.com)
  • Diagnosis is based on lymph node, bone marrow, or tissue morphology of centrocytic lymphocytes, small cell type, or blastoid variant cells. (nih.gov)
  • In particular embodiments, the present disclosure involves the knockout (or knockdown, in certain cases) of genes in particular lymphoid cells, such as tumor-infiltrating lymphocytes (TILs) or engineered T cells, for example, to improve the function of the cells within the tumor microenvironment. (justia.com)
  • Regulatory T lymphocytes (Treg) control the activity of immune cells and suppress the development of inflammation, maintaining the immune balance necessary for the body. (genescells.ru)
  • Gershon R.K., Kondo K. Cell interactions in the induction of tolerance: the role of thymic lymphocytes. (genescells.ru)
  • 27. Engraftment of primates with G-CSF mobilized peripheral blood CD34+ progenitor cells expanded in G-CSF, SCF and MGDF decreases the duration and severity of neutropenia. (nih.gov)
  • Bristol Myers Squibb (NYSE: BMY) today announced six-year results from Part 1 of the Phase 3 CheckMate -227 trial, which continues to demonstrate long-term, durable survival benefits of Opdivo (nivolumab) plus Yervoy (ipilimumab) compared to chemotherapy in the first-line treatment of patients with metastatic non-small cell lung cancer (mNSCLC), regardless of PD-L1 expression levels. (minyanville.com)
  • Opdivo plus Yervoy -based combinations have shown significant improvements in OS in six Phase 3 clinical trials in five tumors to date: metastatic NSCLC, metastatic melanoma, advanced renal cell carcinoma, malignant pleural mesothelioma and esophageal squamous cell carcinoma. (minyanville.com)
  • Tumor vaccines of all types (protein/peptide, viral, DNA/RNA, dendritic cell, tumor cell) and formulations to induce or amplify tumor-specific immunity. (nih.gov)
  • Recent years have witnessed efforts to induce more selective immune responses via dendritic cell vaccines, autologous and engineered T-cell therapy, and immune checkpoint blockade. (jnccn.org)
  • Lesions are caused by bone replacement by expanding plasmacytomas or by cytokines that are secreted by malignant plasma cells that activate osteoclasts and suppress osteoblasts, leading to bone loss. (msdmanuals.com)
  • We have been using both Neupogen and a biosimilar G-CSF) Zarzio® (as a mobilizing agent since February 2014 for both allogenic and autologous stem cell transplantations. (bvsalud.org)
  • Aetna considers tandem autologous hematopoietic cell transplantion (auto-auto) or tandem autologous hematopoietic cell transplantation followed by allogenic hematopoietic cell transplantation (auto-allo) experimental and investigational for NHL due to a lack of adequate evidence in the peer-reviewed published medical literature of their safety and effectiveness. (aetna.com)
  • Currently, there are no clinically effective, FDA-approved monoclonal antibody or autologous T-cell therapies for MM (see, e.g. (justia.com)
  • 26. G-CSF-mobilized peripheral blood progenitor cells for allogeneic transplantation: safety, kinetics of mobilization, and composition of the graft. (nih.gov)
  • There are shared interests with Transplantation, Tolerance and Tumor Immunology (TTT) in transplantation and graft vs. host disease. (nih.gov)
  • Applications that focus on the hematopoietic stem cell transplantation as a part of cancer treatment and the immune toxicities associated with graft vs host disease may be reviewed in CIC. (nih.gov)
  • Autologous stem cell transplantation uses the patient's stem cells and does not cause graft versus host disease (GVHD) and has a very low risk of death, while minimizing the number of cancer cells. (mycancergenome.org)
  • To minimize the chance of graft-versus-host disease (GVHD), the stem cells will have most, but not all, of the T cells removed, using a newer, experimental approach of a well-established technology. (researcherprofiles.org)
  • Allogeneic transplantation produces durable remissions in a subset of patients, albeit at the cost of graft- versus-host disease. (jnccn.org)
  • Nonanastomotic biliary strictures are a major complication after liver transplantation, resulting in cholestasis and cholangitis and, frequently, in the use of biliary interventions or even retransplantation (i.e. transplantation of a new liver graft and removal of the first graft). (leyastat.com)
  • 3,4] In PTLD following both hematopoietic and solid organ transplantation, more than 80% of PTLDs are of B-cell origin. (cancernetwork.com)
  • With systemic and organ-specific autoimmune reactions, as well as organ transplantation, a decrease in the function of Tregs is observed. (genescells.ru)
  • NK-cell malignancies show a geographical predilection for Asian and South American populations and are rare in the west. (medscape.com)
  • Cite this: Diagnosis and Management of Natural Killer-cell Malignancies - Medscape - Oct 01, 2010. (medscape.com)
  • SMILE protocol for advanced stage and relapsed natural killer cell malignancies. (medscape.com)
  • Kepivance is a mucocutaneous epithelial human growth factor indicated to decrease the incidence and duration of severe oral mucositis in patients with hematologic malignancies receiving myelotoxic therapy in the setting of autologous hematopoietic stem cell support. (nih.gov)
  • Kepivance was not effective in decreasing the incidence of severe mucositis in patients with hematologic malignancies receiving myelotoxic therapy in the setting of allogeneic hematopoietic stem cell support. (nih.gov)
  • 3.2 HDC with ABMT or autologous PSCT is covered in the treatment of the following malignancies. (health.mil)
  • In summary, the SFB1530 will undertake a holistic and interdisciplinary effort, which will create a comprehensive inventory of the major patho-mechanisms that define high-risk B cell malignancies in their specific microenvironment as a molecular framework for mechanism-based therapies. (sfb1530.de)
  • Sensitization with AAPCs also permitted expansion of IFN-γ + cytotoxic effector cells against subdominant epitopes that were either absent or in low frequencies in T cells sensitized with autologous APCs. (aai.org)
  • To evaluate the tumor microenvironment and cytokine production by immune effector cells before and after flotetuzumab treatment. (ucsf.edu)
  • T cells generated were CD8 + , IFN-γ + , and exhibited HLA-restricted CMVpp65-specific cytotoxicity. (aai.org)
  • Low or absent natural killer (NK) cell and CD8+ cytotoxic T lymphocyte (CTL) cytotoxicity is one of the hallmarks of HLH and leads to impaired regulation of the immune response [ 4 ]. (biomedcentral.com)
  • The unique structure of CAR endows T cell tumor specific cytotoxicity and resistance to immunosuppressive microenvironment in cancers, which helps patients to better tackle the issue of immunological tolerance. (biomedcentral.com)
  • Each of those cell sources has specific advantages and disadvantages, and each has found particular clinical applications. (medscape.com)
  • 2012 Good Manufacturing Practices for stored clinical bone marrow stromal cell products developed. (nih.gov)
  • 21. Ex vivo expansion of megakaryocyte progenitors: effect of various growth factor combinations on CD34+ progenitor cells from bone marrow and G-CSF-mobilized peripheral blood. (nih.gov)
  • 24. Mobilization of peripheral blood progenitor cells (PBPC) through a combination of chemotherapy and G-CSF in breast cancer patients and a possibility of unprocessed whole blood collection. (nih.gov)
  • B lood cell differentiation begins with multipotent hematopoietic progenitor cells (HPCs), which are located in the marrow spaces of the bone. (nationalacademies.org)
  • As the cells reproduce, they commit to a particular task or cell line and become known as committed progenitor cells . (nationalacademies.org)
  • These committed progenitor cells are difficult to discern from the original multipotent cells but can be cultured to form colonies of specific types of blood cells (Guyton and Hall, 2000). (nationalacademies.org)
  • Umbilical cord blood is a rich source of these committed progenitor cells and, presumably, multipotent HPCs (Knudtzon, 1974). (nationalacademies.org)
  • Patients were eligible as consolidation following standard induction chemotherapy or as part of salvage therapy. (informationalwebs.com)
  • Third-Party BK Virus-Specific Cytotoxic T Lymphocyte Therapy for Hemorrhagic Cystitis Following Allotransplantation. (stembook.org)
  • Embodiments of the disclosure encompass methods and compositions related to cell therapy treatment, including for cancer. (justia.com)
  • Embodiments of the disclosure include at least the fields of cell biology, molecular biology, immunology, cell therapy, and medicine. (justia.com)
  • In particular embodiments, the cells are modified to reduce expression completely or partially of multiple endogenous genes in the cells, and such modifications allow the cells of the therapy to kill cancer cells more effectively than if the cells were not so modified. (justia.com)
  • Immune therapy has emerged as a promising area of cancer therapeutics based on its potential for tumor selectivity and targeting of chemotherapy-resistant clones. (jnccn.org)
  • These results suggest that MC delivery via microvesicles can mediate gene transfer to an extent that enables effective prodrug conversion and tumor cell death such that it comprises a promising approach to cancer therapy. (regenerativemedicine.net)
  • The level of gene transfer in blood cells and immune function will be measured as endpoints. (researcherprofiles.org)
  • While in the course of oncogenesis, the activity of Tregs prevents the development of an adequate immune response to tumor antigens, promotes the processes of angiogenesis and uncontrolled growth of transformed cells. (genescells.ru)
  • BACKGROUND In the Middle East, there is lack of data on peripheral blood CD34+stem cells mobilization by using biosimilar filgrastim. (bvsalud.org)
  • All patients and healthy donors who received either the biosimilar G-CSF (Zarzio®) or original G-CSF (Neupogen®) for mobilization of CD34+ stem cells were included in the study. (bvsalud.org)
  • RESULTS A total of 114 patients, including 97 cancer patients and 17 healthy donors, underwent successful CD34+ stem cell mobilization using G-CSF with chemotherapy (35 with Zarzio® +chemotherapy, 39 with Neupogen® +chemotherapy) or G-CSF as monotherapy (14 with Zarzio®, 9 with Neupogen®) in autologous transplantation. (bvsalud.org)
  • The primary goal was to determine and compare the rate of successful harvest and amount of CD34+ stem cells collected in either adult cancer patients or healthy donors between Zarzio® and Neupogen® groups. (bvsalud.org)
  • The goal of stem cell "transplantation" or "rescue" is to reverse the bone marrow suppression caused by either HDC or by a primary bone marrow disease process (e.g., aplastic anemia). (health.mil)
  • In vitro, abrogation of cFLIP cleavage sensitizes cells to tumor necrosis factor(TNF)-induced necroptosis and apoptosis by favoring complex-II formation. (sfb1530.de)
  • 8 Esophageal cancers are histologically classified as squamous cell carcinoma (SCC) or adenocarcinoma, which differ in their etiology, pathology, tumor location, therapeutics , and prognosis. (jnccn.org)
  • 2.1 HDC is defined as the use of cytotoxic therapeutic agents (that are otherwise approved by the U.S. Food and Drug Administration (FDA) for general use in humans) in dosages and/or frequencies of dosage that exceed the FDA labeling for the agent. (health.mil)
  • [ 1 ] There exists a bipotential T-/NK-cell progenitor, which can develop into the NK-cell lineage (without rearrangement of the T-cell receptor [ TCR ] genes) or commit alternatively to the T-cell lineage (with rearrangement of the TCR genes). (medscape.com)
  • A few cases have shown rearrangement of the T-cell receptor β gene. (wikipedia.org)
  • Thus, in specific embodiments, the expression of SIT1, BST2, and PD-1 is altered through genetic modification that results in improved T cell resistance or TIL resistance to immunosuppression compared to T cells or TIL, respectively, that do not have deliberate modification of expression of these genes. (justia.com)
  • Embodiments of the disclosure allow for improved T cell resistance to immunosuppression compared to T cells with un-altered expression of SIT1, BST2, and PD-1, including to overcome immunosuppression in the tumor microenvironment. (justia.com)